CHAMPIONS ONCOLOGY, INC. Earnings Per Share Disclosure
| Year Ended April 30, | |||||||||||
| 2025 | 2024 | ||||||||||
| Basic and diluted net income (loss) per share computation (dollars in thousands): | |||||||||||
| Net income (loss) attributable to common stockholders | $ | 4,701 | $ | (7,276) | |||||||
| Weighted Average common shares - basic and diluted | 13,659,786 | 13,547,604 | |||||||||
| Basic and diluted net income (loss) per share | $ | 0.34 | $ | (0.54) | |||||||
| Diluted income (loss) per share computation | |||||||||||
| Net income (loss) attributable to common stockholders | $ | 4,701 | $ | (7,276) | |||||||
| Weighted Average common shares | 13,659,786 | 13,547,604 | |||||||||
| Incremental shares from assumed exercise of stock options | 606,995 | — | |||||||||
| Adjusted weighted average share – diluted | 14,266,781 | 13,547,604 | |||||||||
| Diluted net income (loss) per share | $ | 0.33 | $ | (0.54) | |||||||
| Year Ended April 30, | |||||||||||
| 2025 | 2024 | ||||||||||
| Stock options | 126,353 | 1,919,497 | |||||||||
| Total common stock equivalents | 126,353 | 1,919,497 | |||||||||
Want the next CHAMPIONS ONCOLOGY, INC. earnings per share disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment CHAMPIONS ONCOLOGY, INC.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Jul 23, 2025 | Showing above |
| 2024 | Jul 19, 2024 | |
| 2023 | Jul 24, 2023 | |
| 2022 | Jul 22, 2022 | |
| 2021 | Jul 26, 2021 | |
| 2020 | Jul 28, 2020 | |
| 2019 | Jul 29, 2019 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.